1-3 of 3
Adalbert Weißmann
Close
Sort by
Journal Articles

Lenalidomide and Dexamethasone for Acute Light Chain-Induced Renal Failure: Final Results of a Phase II Study

Heinz Ludwig, Univ. Prof. Dr., Elisabeth Rauch, Thomas Kuehr, MD, Adam Zdenek, MD, Adalbert Weissmann, MD, Hedwig Kasparu, MD, Eva-Maria Autzinger, MD, Daniel Heintel, MD, Richard Greil, MD, Wolfram Poenisch, MD, Niklas Zojer, MD, Ercan Müldür, MD
Journal: Blood
Blood (2014) 124 (21): 3484.
https://doi.org/10.1182/blood.V124.21.3484.3484
Published: 2014
Journal Articles

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

Clinical Trials & Observations
Heinz Ludwig, Hedwig Kasparu, Clemens Leitgeb, Elisabeth Rauch, Werner Linkesch, Niklas Zojer, Richard Greil, Adelheid Seebacher, Ludek Pour, Adalbert Weißmann, Zdeněk Adam
Journal: Blood
Blood (2014) 123 (7): 985–991.
https://doi.org/10.1182/blood-2013-08-521468
Published: 2014
Journal Articles

Rapid Reduction of Light-Chains and Proteinuria in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure Treated with Lenalidomide and Dexamethasone

Heinz Ludwig, MD, Josef Thaler, Jan Koren, Ludek Pour, Ercan Müldür, Martin Schreder, MD, Niklas Zojer, Adalbert Weissmann, Zdenek Adam
Journal: Blood
Blood (2011) 118 (21): 5114.
https://doi.org/10.1182/blood.V118.21.5114.5114
Published: 2011